Prospective, multicenter study of antimicrobial-coated, noncrosslinked, acellular porcine dermal matrix (XenMatrix™ AB Surgical Graft) for hernia repair in all centers for disease control and prevention wound classes: 24-month follow-up cohort

• Type of Material: Article
• Authors: Obeid N Hahi, Washington University School of Medicine in St. Louis; George Velmahos, Massachusetts General Hospital; Jeffrey E Janis, The Ohio State University; Stephen J Kovach, University of Pennsylvania; Susan F McLean, Texas Tech University Health Sciences Center El Paso; Reza Askari, Brigham and Women's Hospital; Courtney A Sommer, Duke University Medical Center; Suresh Agarwal, Duke University Medical Center; Jahnavi Srinivasan, Emory University; Alex K Wong, City of Hope National Med Center; Andrea Pakula, Kern Medical; Edward P Miranda, University of California, San Francisco; Kerry Breen, Massachusetts General Hospital; Mark Shapiro, Duke University Medical Center; Corey R Deeken, Covalent Bio, LLC; Cody R Stringer, Covalent Bio, LLC; Reed J McGraw, University of Pennsylvania; Corey Bascone, University of Pennsylvania; Robert G Martindale, Oregon Health & Science University
• Language: English
• Date: 2023-05-01
• Publisher: Wolters Kluwer Health, Inc.
• Publication Version: Final Published Version
• Copyright Statement: © 2023 the Author(s). Published by Wolters Kluwer Health, Inc
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1097/MS9.0000000000000695
• Title of Journal or Parent Work: Annals of Medicine and Surgery
• Volume: 85
• Issue: 5
• Start Page: 1571
• End Page: 1577
• Grant/Funding Information: This project was sponsored by Davol Inc. (Warwick, RI), a subsidiary of C. R. Bard, Inc. (Franklin Lakes, NJ). Bard and Davol have joined BD (Franklin Lakes, NJ).
• Keywords: XenMatrix AB surgical graft; surgical site occurrence; hernia repair; minocycline; rifampin; porcine dermal matrix
• Research Categories: Health Sciences, Medicine and Surgery

Abstract

Background: Prospective, multicenter, single-arm study of antimicrobial-coated, noncrosslinked, acellular porcine dermal matrix (AC-PDM) in a cohort involving all centers for disease control and prevention wound classes in ventral/incisional midline hernia repair (VIHR). Materials and methods: Seventy-five patients (mean age 58.6 ± 12.7 years; BMI 31.3 ± 4.9 kg/m2) underwent ventral/incisional midline hernia repair with AC-PDM. Surgical site occurrence (SSO) was assessed in the first 45 days post-implantation. Length of stay, return to work, hernia recurrence, reoperation, quality of life, and SSO were assessed at 1, 3, 6, 12, 18, and 24 months. Results: 14.7% of patients experienced SSO requiring intervention within 45 days post-implantation, and 20.0% thereafter (> 45 d post-implantation). Recurrence (5.8%), definitely device-related adverse events (4.0%), and reoperation (10.7%) were low at 24 months; all quality-of-life indicators were significantly improved compared to baseline. Conclusion: AC-PDM exhibited favourable results, including infrequent hernia recurrence and definitely device-related adverse events, with reoperation and SSO comparable to other studies, and significantly improved quality of life.